Judith Trotman

11.6k total citations · 1 hit paper
159 papers, 3.6k citations indexed

About

Judith Trotman is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Judith Trotman has authored 159 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Pathology and Forensic Medicine, 76 papers in Genetics and 48 papers in Oncology. Recurrent topics in Judith Trotman's work include Lymphoma Diagnosis and Treatment (114 papers), Chronic Lymphocytic Leukemia Research (76 papers) and Viral-associated cancers and disorders (26 papers). Judith Trotman is often cited by papers focused on Lymphoma Diagnosis and Treatment (114 papers), Chronic Lymphocytic Leukemia Research (76 papers) and Viral-associated cancers and disorders (26 papers). Judith Trotman collaborates with scholars based in Australia, United States and Italy. Judith Trotman's co-authors include Michel Meignan, Sally F. Barrington, Martin Hutchings, Rodney J. Hicks, Bruce D. Cheson, Alberto Biggi, Emanuele Zucca, Roland Hustinx, Lale Kostakoğlu and Lawrence H. Schwartz and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Judith Trotman

145 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

2014 989 citations Sally F. Barrington, N. George Mikhaeel et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Judith Trotman

Since Specialization

Citations

This map shows the geographic impact of Judith Trotman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Trotman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Trotman more than expected).

Fields of papers citing papers by Judith Trotman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Trotman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Trotman. The network helps show where Judith Trotman may publish in the future.

Co-authorship network of co-authors of Judith Trotman

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Trotman. A scholar is included among the top collaborators of Judith Trotman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Trotman. Judith Trotman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient Perception of the Relevance of Quality-of-Life Questionnaires in Waldenström Macroglobulinaemia: An International Survey 2025 ·Cancers ·Jahanzaib Khwaja, (unknown), (unknown), (unknown), (unknown), David Young, Sosana Delimpasi, Shirley D’Sa, Judith Trotman, Charalampia Kyriakou	0
2	Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton’s tyrosine kinase inhibitors in Waldenström macroglobulinemia 2025 ·Scientific Reports ·(unknown), Chansavath Phetsouphanh, Zong Hong Zhang, Rowena A. Bull, Lok Bahadur Shrestha, (unknown), Raymond H. Y. Louie, Fabio Luciani, C. Mee Ling Munier, (unknown), Elizabeth Keoshkerian, (unknown), (unknown), Alexander Wong, Judith Trotman, Anthony D. Kelleher, Sarah C. Sasson	0
3	Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study 2024 ·Blood ·Meghan C. Thompson, Ricardo Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfò, Xiangmei Chen, Kunthel By, (unknown), Daniel O. Persky, Amit Agarwal, John F. Seymour	14
4	Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance 2024 ·Internal Medicine Journal ·Joshua W.D. Tobin, Greg Hapgood, Anna Johnston, Chan Y. Cheah, (unknown), Judith Trotman, (unknown), Belinda A. Campbell, (unknown), Michael MacManus, Mark Hertzberg, Eliza A. Hawkes	2
5	Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial 2023 ·Annals of Oncology ·Anne‐Ségolène Cottereau, (unknown), Judith Trotman, Pierre Feugier, Loretta J. Nastoupil, Emmanuel Bachy, Ian W. Flinn, Corinne Haïoun, Loïc Ysebaert, Nancy L. Bartlett, Hervé Tilly, Olivier Casasnovas, Renato Pietro Ricci, (unknown), Irène Buvat, Michel Meignan, Franck Morschhauser	15
6	A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials 2023 ·SHILAP Revista de lepidopterología ·Lale Kostakoğlu, Maurizio Martelli, Laurie H. Sehn, Andrew Davies, Marek Trněný, Michael Herold, Umberto Vitolo, Wolfgang Hiddemann, Judith Trotman, Andrea Knapp, Federico Mattiello, Tina Nielsen, Deniz Şahin, Gila Sellam, Carol Ward, Anas Younes	1
7	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study 2022 ·Clinical Cancer Research ·Grzegorz S. Nowakowski, Dok Hyun Yoon, Anthea Peters, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, (unknown), Mark Winderlich, Nuwan Kurukulasuriya, Sumeet Ambarkhane, Georg Heß, Gilles Salles	16
8	Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study 2022 ·Cancer Epidemiology ·Michael K. Odutola, Marina T. van Leeuwen, Jennifer Turner, Fiona Bruinsma, John F. Seymour, H. Miles Prince, Samuel T. Milliken, Mark Hertzberg, Judith Trotman, Stephen Opat, (unknown), Fernando Roncolato, Emma Verner, Michael Harvey, Campbell Tiley, Craig Underhill, Geza Benke, Graham G. Giles, Claire M. Vajdic	2
9	Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial 2021 ·Clinical Cancer Research ·Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios Α. Dimopoulos	27
10	Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma 2021 ·Blood Advances ·Karthik Nath, Soi Cheng Law, Muhammed B. Sabdia, Jay Gunawardana, Lilia Merida de Long, David P. Sester, (unknown), (unknown), Joshua W.D. Tobin, (unknown), (unknown), Donna J. Cross, Robert Bird, Sanjiv Jain, Colm Keane, Dipti Talaulikar, Judith Trotman, W. Phillip Law, Maher K. Gandhi	12
11	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up 2020 ·Blood ·Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Muñoz, Alessandra Tedeschi, Andrew W. Roberts, John F. Seymour, Siminder Atwal, Yiling Yu, William Novotny, Eric Holmgren, (unknown), James Hilger, Jane Huang, Constantine S. Tam	73
12	PF481 UPDATED SAFETY AND EFFICACY DATA IN A PHASE 1/2 TRIAL OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA (WM) TREATED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111) 2019 ·HemaSphere ·Judith Trotman, Stephen Opat, Paula Marlton, David Gottlieb, David Simpson, Gavin Cull, David Ritchie, Emma Verner, Javier Muñoz, Alessandra Tedeschi, Jennifer J. Huang, William Novotny, Medhat Osman, Siminder Atwal, John F. Seymour, Andrew W. Roberts, Constantine S. Tam	3
13	Front‐line management of indolent non‐Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma 2019 ·Internal Medicine Journal ·Chan Y. Cheah, Stephen Opat, Judith Trotman, Paula Marlton	10
14	Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety 2018 ·Journal of Clinical Oncology ·Wolfgang Hiddemann, Anna Maria Barbui, Miguel Canales, Paul Cannell, Graham P. Collins, Jan Dürig, Roswitha Forstpointner, Michael Herold, Mark Hertzberg, Magdalena Klánová, John Radford, John F. Seymour, Kensei Tobinai, Judith Trotman, (unknown), Günter Fingerle‐Rowson, (unknown), Tina Nielsen, Robert Marcus	144
15	Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study 2018 ·Blood ·Anne‐Ségolène Cottereau, Annibale Versari, Stefano Luminari, Jehan Dupuis, Loïc Chartier, Olivier Casasnovas, Alina Berriolo-Riedinger, Massimo Menga, Corinne Haïoun, Hervé Tilly, Vittoria Tarantino, Massimo Federico, Gilles Salles, Judith Trotman, Michel Meignan	52
16	Front‐line management of non‐Hodgkin lymphoma in Australia. Part 1: follicular lymphoma 2018 ·Internal Medicine Journal ·Judith Trotman, Chan Y. Cheah, Paula Marlton, Stephen Opat	2
17	Comparison Of Contrast-Enhanced Ct-Based Response With Pet Assessment After First-Line Therapy For Follicular Lymphoma In The Phase Iii Gallium Study 2017 ·Haematologica ·Judith Trotman, Sally F. Barrington, David Belada, Michel Meignan, (unknown), Claire Owen, (unknown), (unknown), Guenter Fingerle-Rowson, (unknown), Tina Nielsen, (unknown), Wolfgang Hiddemann, Roy Marcus, Andrew Davies	1
18	Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies 2017 ·Blood ·Gavin Cull, Stephen Opat, Judith Trotman, James Hilger, Xiaoping Zhang, Shibao Feng, Sunhee Ro, Jane Huang, Constantine S. Tam	2
19	Formalising multidisciplinary peer review: developing a haematological malignancy‐specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence‐based clinical practice 2016 ·Internal Medicine Journal ·Judith Trotman, (unknown), Yiu Lam Kwan, Jane Estell, Julie Fletcher, (unknown), Kenneth Lee, (unknown), Jennifer Curnow, Alessandra Bianchi, (unknown), Emma Verner, Robin Gasiorowski, (unknown), Ilona Cunningham	5
20	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group breakdown → 2014 ·Journal of Clinical Oncology ·Sally F. Barrington, N. George Mikhaeel, Lale Kostakoğlu, Michel Meignan, Martin Hutchings, Stefan Müeller, Lawrence H. Schwartz, Emanuele Zucca, Richard I. Fisher, Judith Trotman, Otto S. Hoekstra, Rodney J. Hicks, Michael O’Doherty, Roland Hustinx, Alberto Biggi, Bruce D. Cheson	989

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact